Mark Freedman, MD: Early Intervention With Interferon Beta-1b for Patients Presenting With CIS
March 28th 2019The director of the multiple sclerosis research unit at Ottawa Hospital spoke about the results of BENEFIT 15 that support early intervention of interferon beta-1b treatment at or shortly after CIS.
CSF Immunoglobulin G May Be Useful for Multiple Sclerosis Diagnosis
March 28th 2019With the lack of a gold standard diagnostic test, a study has shown through latent class analysis that cerebrospinal fluid immunoglobulin G may be a practical tool for determining the onset of MS in patients, particularly those who tested negative under the 2005 and 2010 McDonald criteria.
Trofinetide Triumphs in Phase 2 Study of Rett Syndrome
March 28th 2019Of the 5 syndrome-specific efficacy measurements, trofinetide showed statistical benefits for patients with Rett syndrome on the Rett Syndrome Behavior Questionnaire, Clinical Global Impression Scale-Improvement, and the RTT Clinician Domain Specific Concerns-Visual Analog Scale.
Improving Pediatric Headache Care Through Better Performance on Headache Quality Measures
March 28th 2019Implementing evidence-based practices consistent with the AAN Headache Quality Measures has the potential to improve the quality of care in this patient population, however, additional study is required to determine if better process performance produces better outcomes.
JZP-258 Displays Improvements in Cataplexy, Daytime Sleepiness for Patients With Narcolepsy
March 27th 2019Topline data showed that the novel oxybate candidate demonstrated significant differences compared to placebo in the change in the weekly number of cataplexy attacks and the change in Epworth Sleepiness Scale score, the primary and secondary end points, respectively.
RG6042 on Horizon as a Potential Treatment for Huntington Disease
March 27th 2019The associate group medical director and clinical science leader for the IONIS/Roche HTT Rx program at Roche/Genentech neuroscience spoke about the study design of GENERATION HD1 and the potential impact of RG6042 as a treatment for Huntington disease.
Novel Model Predicts Patients With Epilepsy Who Fail to Achieve Remission Post-Breakthrough
March 27th 2019The novel longitudinal model utilized 4 variables—the presence of seizures, the number of seizures, the number of adverse events, and if treatment was altered—and was ultimately more predictive than a standard Cox model.
Mobile Health Tech Must Be Integrated Into Parkinson Disease Care, MDS Task Force Says
March 26th 2019The Movement Disorder Society Task Force on Technology has released a roadmap for the implementation of new technologies that have reached a level of sophistication, versatility, and wearability for Parkinson disease.
Dementia Care Faces Lack of Safe and Effective Atypical Antipsychotic Treatment
March 22nd 2019Findings from a recent meta-analysis of the number of atypical antipsychotics available for treatment of behavioral and psychological symptoms of dementia suggest that a clear trade-off exists between effectiveness and safety, with no clear winner emerging.
David Leppert, MD: Building a Foundation for Neurofilament Light
March 22nd 2019The therapeutic head of neuroinflammation and pain at Novartis spoke about his desire to work to a point where physicians can use NfL to monitor disease activity, make therapeutic decisions, and give perspective to patients.
Idebenone Reduces Respiratory Function Loss in Duchenne Muscular Dystrophy
March 22nd 2019SYROS study data showed that switching to and maintaining long-term treatment with idebenone was associated with a 50% reduction in the annual rate of decline in forced vital capacity percent of predicted.